Piperacillin Tazobactum
Mechanism :
Piperacillin and tazobactam is an injectable antibacterial combination product consisting of the semisynthetic extended spectrum penicillin effective against the gram-negative organisms like Pseudomonas and Klebsiella species and the b -lactamase inhibitor tazobactam sodium for intravenous administration. It is also effective against S.aureus, H.influenza, Enterobacter.
Indication :
- Pseudomonas infection, not responding to other drugs
- Klebsiella spp infections
Contraindications :
Contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or b-lactamase inhibitors.
Dosing :
Newborn:
80 mg/kg/dose (piperacillin component) IV 3 times daily.
Children:
100 mg/kg/dose (piperacillin component) IV 3 times daily. Max: 4 g/dose
piperacillin and 4.5 g/dose
piperacillin tazobactam.
Adverse Effect :
Serious and occasionally fatal anaphylactic reactions have occurred. Rarely liver disorders, blood dyscrasias and dermatological manifestations have been reported. Rarely renal failure may occur.
Interaction :
Warfarin: Possible prolonged prothrombin time with warfarin.
Aminoglycosides : the mixing of beta-lactam antibiotics with aminoglycosides in vitro can result in substantial inactivation of the aminoglycoside
Probenecid: administered concomitantly prolongs the half-life of piperacillin by and that of tazobactam
Vecuronium: Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium
Methotrexate: Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion
Hepatic Dose :
No dosage adjustments are recommended.